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Pleurotus cornucopiae (Oyster mushroom, Tamogitake) has long been eaten as a functional food for
enhancement of the immune system, but its effectiveness has not beenwell conﬁrmed in humans. To this
end, we set up a double-blind placebo-controlled human clinical trial to investigate the potential of
Oyster mushrooms with respect to the up-regulation of the immune system. The subjects ingested
Oyster mushroom extract for 8 weeks. We measured the serum cytokine levels involved in regulation of
the immune system, including interferon (IFN)-g, interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, and tumor-
necrosis factor (TNF)-a. We found that intake of Oyster mushroom extract elevated IFN-g (P ¼ 0.013) and
IL-12, whereas serum levels of IL-10 and IL-13 and other cytokines were minimally changed. We also
measured natural killer (NK) cell activity, the levels of which tended to increase, but not signiﬁcantly.
Taken together, these facts suggest that Oyster mushrooms have the potential to enhance the immune
system, through Th1 phenotype potentiation as the macrophage-IL-12 e IFN-g pathway. This results in
activation of the cell-mediated immune system as exempliﬁed by up-regulation of NK cell activity. Oyster
mushroom extract may be beneﬁcial for the prevention of various diseases, including infectious diseases
and cancer, due to its stimulation of the immune system.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Various edible mushrooms have been used as functional foods
and as important sources of complementarymedicine beneﬁcial for
the prevention of diseases.1 They have been used as folk medicine
all over the world since ancient times. For example, Agaricus blazei
Murill mushroom is consumed as a food and for its possible me-
dicinal value.2 Its dried fruiting bodies have been used as stimulant
and as an auxiliary treatment of various diseases, including cancer.
Pleurotus species are commonly called Oyster mushrooms.
There are about 40 species of these mushrooms distributed
worldwide in both temperate and tropical zones of the world.3 The
production amount of Oyster mushrooms now ranks second amongversity, Department of Medi-
do 069-8585, Japan. Fax: þ81
ihira).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).the cultivated mushrooms in the world. In Japan, Oyster mush-
rooms of Pleurotus cornucopiae (Tamogitake) with a yellow pileus
are commonly sold in markets. Oyster mushrooms are grown and
harvested in relatively cool-climate areas in Japan, around Hok-
kaido and Tohoku. These mushrooms have been traditionally
consumed by local people to prevent diseases such as hypertension
and cancer.4
The immune system is the body's self-defense system against
infectious diseases, immunodeﬁciencies and cancer growth. The
immune system is a complex involving many white blood cells, e.g.,
macrophages and lymphocytes, proteins and chemicals. A healthy
immune system contains elements that are usually well balanced
with one another. In a compromised immune system, components
are unbalanced and unable to protect the body against harmful
agents or processes.
It has beenwell recognized that Interferon (IFN)-g coordinates a
diverse array of cellular programs through transcriptional regula-
tion of immunomodulatory genes.5 IFN-g is involved in up-
regulation of pathogen recognition, antigen processing and
presentation, cellular proliferation and apoptosis relevant torsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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important role in the integration of signaling and response by other
cytokines such as TNF-a and IL-4 and in pathogen-associated mo-
lecular patterns.
IFN-g plays an important role against infection and tumor
growth. This molecule orchestrates leukocyte attraction and directs
growth, maturation, and differentiation of many cell types, in
addition to enhancing natural killer cell activity by regulating B cell
function in terms of immunoglobulin production and class
switching.6 As negative regulators of IFN-g production, IL-4, IL-10,
transforming growth factor-b, and glucocorticoids are well recog-
nized. In this study, we investigated whether consumption of
Oyster mushroom extract by humans would up-regulate IFN-g and
in turn up-regulate the immune system. We designed a double-
blind, placebo-controlled study to investigate the effectiveness of
Oyster mushroom extract with respect to immune potentiation.
2. Materials and methods
2.1. Subjects
Through screening, we recruited Japanese 100 volunteers and
selected 47 subjects without any medication. At the start of this
trial, 47 subjects (5 males and 42 females, age range 34e64 years)
were enrolled. During screening, subjects with a recent history of
gastrointestinal disorders, pregnancy, severe acute and chronic
diseases, surgery, severe allergic reaction to food, or current use of
any medication were excluded. The clinical intervention was con-
ducted as a double-blind, placebo-controlled trial. At randomiza-
tion, the 47 eligible subjects were randomly assigned to one of two
groups (Oyster mushroom group and placebo group) with adjust-
ment by age, sex, and natural killer (NK) cell activity.
Prior to the start of the trial, 6 persons were excluded because of
health problems, such as low ingestion rate (less than 80%) of test
foods, and intake of prohibited drugs or foods. As a result, 41 per-
sons were subjected to analysis, 21 and 20 for the placebo and the
test meal, respectively. The mean subject age, height, body weight
(BW), bodymass index (BMI), body fat percentage (BFP) and NK cell
activity for each group are reported in Table 1. These data of the
placebo and test groups were not statistically signiﬁcant, indicating
the appropriate allotment of test and placebo groups.
2.2. Study design
The clinical study was conducted as double-blind, placebo-
controlled trail. The time schedule for this clinical study is shown in
Fig. 1. Few clinical studies have been performed to evaluate efﬁcacy
of Oyster mushroom on immune reaction. Based on an experi-
mental results on clinical studies7,8 we hypothesized that 8 week
intake of Oyster mushroom extract would be sufﬁcient to assess the
potential efﬁcacy. The primary endpoint was NK cell activity, andTable 1
Characteristics of the subjects in the placebo and Oyster mushroom intake groups.
Characteristic Oyster mushroom Placebo P-value
Number of subjects n ¼ 20 n ¼ 21 e
Number of males (male %) 2 (10.00%) 2 (9.52%) 0.678
Age (years) 51.25 ± 8.80 50.24 ± 8.70 0.713
Height (cm) 159.50 ± 4.55 158.40 ± 5.32 0.482
Body weight (kg) 53.87 ± 7.07 53.65 ± 7.18 0.924
BMI (kg/m2) 21.21 ± 2.85 21.39 ± 2.88 0.837
Body fat percentage (%) 27.26 ± 6.20 27.82 ± 6.42 0.777
NK cell activity (%) 35.00 ± 10.90 32.62 ± 12.32 0.517
Values shown are mean ± standard deviation (SD). Statistical analysis was per-
formed by Student's t-test for age, height, body weight, BMI, body fat percentage,
and natural killer cell activity, and by chi-square test for gender.secondary endpoints were parameters relevant to Th1/Th2 balance,
including IFN-g, IL-10, IL-12, IL-13, IL-4, IL-5 and TNF-a. In addition,
a set of biomarkers for liver and renal functions were measured to
assess safety of Oyster mushroom extract and placebo.
We performed body composition (BW, BMI, and BFP) mea-
surements at baseline (week 0) and post-intervention (weeks 4 and
8) for the two groups. At all three time points, a medical interview,
check of vital signs, blood sample collection, and hematological
examinations were performed as well. During the course of this
study, subjects were advised to keep diaries of their daily activities,
including food consumption, drug intake and exercise.
2.3. Test meal preparation
The test meals (Oyster mushroom extract and placebo) were
kindly provided by Three B Co., Inc. (Nanporo-Cho, Hokkaido,
Japan), and contained 100% water extract of Oyster mushroom
(Tamogitake) extract (80 mL per pouch; Table 2). Oyster mush-
rooms contained b-glucan 24 mg/meal, whereas the placebo con-
tained no b-glucan. Other than b-glucan contents, the test meal and
placebo were not signiﬁcantly different except that sodium content
was higher in the placebo (64 mg/meal) than in Oyster mushroom
extract (5.7 mg/meal). The placebo contained various materials:
water, tea (0.5%), oyster sauce (0.5%) and caffeine-free coffee (0.1%)
for coloring. For preparation, in brief, the fruit bodies of Oyster
mushroom were directly extracted with water at 94 C for 10 min.
After concentration, the insoluble parts were removed through
ﬁltration of 0.2 mm. For the last 15 years, no serious complaints
about Oyster mushroom extract have been reported. The meal was
produced and prepared under ISO9001.
2.4. Physical and hematological examination
Blood sampleswere taken for testingon the startingdayandafter
4 and 8 weeks of ingestion of Oyster mushroom extract. In addition
to the medical interview by a doctor, body composition (BW, BMI,
and BFP) were measured. Vital signs (blood pressure upon arrival,
pulse rate, body temperature) were also taken. General blood tests
included complete blood count (CBC) [white blood cells (WBC), red
blood cells (RBC), hemoglobin (Hb), hematocrit (Ht), and platelet
count (Plt)], liver function [aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gammaglutamyl transpeptidase (g-
GTP), alkalinephosphatase (ALP), and lactatedehydrogenase (LDH)],
renal function [blood urea nitrogen (BUN), creatinine (CRE), and
ureic acid (UA)], blood lipid proﬁle [total cholesterol (TC), low den-
sity lipoprotein cholesterol (LDL-C), high density lipoprotein
cholesterol (HDL-C), and Triglyceride (TG)], and blood glucose pro-
ﬁle [fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c)].
The hematological examinations were performed by Sapporo
Clinical Laboratory, Inc. (Sapporo, Japan). Each subject's body
composition and blood pressure were measured with a body
composition analyzer DC-320 (Tanita Corp, Tokyo, Japan) and an
Omron HEM-7080IC automatic blood pressure monitor (Omron
Colin Co., Ltd., Tokyo, Japan).
2.5. Cytokine assay by multiplex assays
Secretion of large amounts of IFN-g (IL-4) is the deﬁning feature
of Th1 (Th2) cells, respectively. These cytokines function to directly
promote cell-mediated immunity (e.g., IFN-g) or humoral immu-
nity (e.g., IL-4) and to reciprocally antagonize each other's action. To
study this, multiplex beads kits were purchased from LINC
Research. Cytokines analyzed in duplicate by each kit included
IFN-g, IL-10, IL-12, IL-13, IL-4, IL-5 and TNF-a. Each multiplex assay
was performed in duplicate on two different occasions according to
Fig. 1. Time schedule (in weeks) for this clinical study. Hematological measurement was conducted at baseline (week 0), and weeks 4 and 8.
Table 2
Composition of Oyster mushroom compared with placebo per 80 ml.
Component Oyster mushroom Placebo
Calories (kcal) 2.4 2.1
Water (g) 97.9 80.5
Proteins (g) 0.9 0.0
Lipids (g) 0.1 0.0
Carbohydrates (g) 0.5 0.4
Ash (g) 0.3 0.3
Sodium (mg) 5.7 64
b-glucan (mg) 24 e
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kine were generated using the reference cytokine concentrations.
2.6. NK cell activity
Chromium-51 (51Cr) release assay was used for quantiﬁcation of
cytotoxicity to measure NK cell activity.9 The assay was conducted
by SRL (Hachioji City, Tokyo, Japan). In brief, target cells are labeled
with 51Cr, the label is then released from the target cells by cytol-
ysis. The label was isolated by centrifuging the samples and col-
lecting the supernatants. Supernatants from centrifugation were
counted directly in a gamma counter.
2.7. Ethics committee
All subjects provided written informed consent before under-
going any study-related tests, and the study protocol was approved
by the Ethics Committee of Hokkaido Information University (a
certiﬁcate number; 2015-09). The study protocol conformed to the
Helsinki Declaration and was registered at the UMIN Clinical Trial
Registration System (certiﬁcate number UMIN000015208).
2.8. Statistical analysis
The means and standard deviations of subject characteristics
were calculated for each group. Changes in subject values were
analyzed using Student's t-test comparing means between the test
group and the placebo group. To test for normality the Shapir-
oeWilk Test was used. The appropriate sample sizewas statistically
determined to obtain a power of 80% with an alpha of 0.05. This
study was planned as a feasibility study, but the minimum size
needed to detect. We referred to our previous in-house studies
relevant to NK cell activities using a mushroom extract, active
hexose correlated compounds (AHCC)10 as well as immune
enhancement of immune system by Lactobacillus plantarum.11 In
order to demonstrate increase of NK cell activity, a sample size of 20
was required under the assumption that increase of NK cell activity
is 5% with a standard deviation of 5.5%. Assuming a 10% loss to
follow-up, we set the total sample size at 47. Statistical analyseswere performed using SPSS Statistic 19 (IBM, Armonk, NY, USA). P-
values <0.05 were considered signiﬁcant.
3. Results
3.1. Physical parameters and blood pressure
We calculated mean values and standard deviations for physical
measurement at weeks 0, 4, and 8 after ingestion of test foods for
47 subjects. As for BW, BMI, BFP, and blood pressure, their mean
values and standard deviations at the three points 0, 4, and 8 weeks
after ingestion were described (Table 3).
We found no adverse effects originated from either Oyster
mushroom extract or placebo. During the current study, we per-
formed visual analog scale (VAS) as for awakening, mood, eager-
ness, comfort, fatigability, concentration, and appetite. Among
them, we did not ﬁnd any statistically signiﬁcant improvement, but
the levels of awakening (P ¼ 0.131) and concentration (P ¼ 0.172)
were relatively improved by the intake of Oyster mushroom extract
in comparison with placebo (data not shown).
3.2. Levels of biomarkers for CBC, liver and renal function, lipid and
glucose metabolism
We examined the levels of several biomarkers of CBC, liver and
renal functions, and lipid and glucose metabolism. No abnormal
changes were found for CBC (WBC, RBC, Hb, Ht, and Plt), liver
function (AST, ALT, g-GTP, ALP, and LDH), and renal function (BUN,
CRE, and UA) after the ingestion of Oyster mushroom at either 4 or
8 weeks (Table 4). Likewise, blood lipid proﬁle (TC, LDL-C, HDL-C,
and TG) showed no abnormality. Minimal differences were
observed between the Oyster mushroom and placebo groups in the
parameters of glucose metabolism (FPG and HbA1c). These results
show that ingestion of Oyster mushroom is safe in terms of lipid
and glucose metabolism, and liver and renal functions.
3.3. Cytokine proﬁle
As for Th1-type cytokines, the plasma level of IFN-g and IL-12
were found to increase with Oyster mushroom consumption
(Fig. 2). In particular, IFN-g, a strong stimulator of NK cells,
increased signiﬁcantly by Oyster mushroom intake compared to
the placebo at week 8 (P ¼ 0.013). Even though statistically insig-
niﬁcant, the IL-12 level tended to be increased by Oyster mushroom
extract compared to the placebo at week 8 (P ¼ 0.101).
As for Th2-type cytokines, we measured plasma levels of IL-10
and IL-13. The former, IL-10, is known to inhibit secretion of
various cytokines by Th1-type cells, macrophages and dendritic
cells. Plasma level of this cytokine was minimally changed by the
intake of Oyster mushroom extract at week 8 (Fig. 3).
Table 3
Physical parameters and BP.
Week 0 Week 4 Week 8
BW (kg) Oyster mushroom 53.33 ± 6.79 53.54 ± 6.69 53.72 ± 6.60
Placebo 56.20 ± 13.02 56.28 ± 13.36 56.44 ± 13.27
BMI Oyster mushroom 21.10 ± 2.76 21.17 ± 2.70 21.24 ± 2.66
Placebo 21.78 ± 3.83 21.81 ± 3.93 21.97 ± 3.85
BFP (%) Oyster mushroom 27.62 ± 6.35 26.97 ± 6.56 28.31 ± 6.13
Placebo 28.23 ± 6.42 28.43 ± 6.31 28.64 ± 6.39
SBP (mmHg) Oyster mushroom 114.59 ± 18.68 115.45 ± 15.45 115.68 ± 20.61
Placebo 110.84 ± 17.23 116.04 ± 18.99 113.67 ± 17.81
DBP (mmHg) Oyster mushroom 71.68 ± 13.74 71.55 ± 10.82 72.14 ± 9.70
Placebo 70.64 ± 9.78 74.36 ± 11.49 73.08 ± 10.67
Values are mean ± standard deviation (SD). BW; body weight, BMI; body mass index, BFP; body fat percentage, SBP; systolic blood pressure, DBP; diastolic blood pressure.
Table 4
Biochemical data.
Week 0 Week 4 Week 8
WBC (103/ml) Oyster mushroom 4.75 ± 1.24 4.65 ± 1.20 4.80 ± 1.33
Placebo 5.50 ± 1.25 5.40 ± 1.38 5.51 ± 1.47
RBC (104/ml) Oyster mushroom 444.05 ± 45.13 440.95 ± 47.55 447.45 ± 48.15
Placebo 455.92 ± 48.96 452.48 ± 47.42 448.46 ± 47.05
Hb (g/dl) Oyster mushroom 13.05 ± 1.69 13.05 ± 1.68 13.29 ± 1.68
Placebo 13.63 ± 1.55 13.62 ± 1.50 13.57 ± 1.46
Ht (%) Oyster mushroom 40.61 ± 3.98 40.13 ± 4.04 40.85 ± 3.99
Placebo 42.13 ± 4.08 41.73 ± 3.74 41.48 ± 3.64
Plt (104/ml) Oyster mushroom 23.72 ± 5.58 24.10 ± 5.72 24.69 ± 7.30
Placebo 22.49 ± 5.47 23.37 ± 5.52 23.33 ± 4.73
AST (U/l) Oyster mushroom 21.32 ± 3.78 22.77 ± 7.70 22.77 ± 6.90
Placebo 23.16 ± 5.91 21.84 ± 4.84 21.42 ± 5.38
ALT (U/l) Oyster mushroom 18.23 ± 5.50 18.14 ± 6.61 19.18 ± 7.65
Placebo 20.08 ± 11.65 18.00 ± 9.20 18.54 ± 10.23
g-GTP (U/l) Oyster mushroom 26.68 ± 14.47 28.00 ± 19.46 30.45 ± 22.25
Placebo 21.72 ± 10.63 20.40 ± 10.97 20.00 ± 9.56
ALP (U/l) Oyster mushroom 198.50 ± 41.40 204.36 ± 61.27 208.73 ± 48.36
Placebo 188.60 ± 51.06 180.36 ± 43.08 188.13 ± 52.36
LDH (U/l) Oyster mushroom 195.91 ± 24.09 201.77 ± 34.44 209.95 ± 35.13
Placebo 207.44 ± 42.87 204.76 ± 34.75 204.17 ± 34.87
BUN (mg/dl) Oyster mushroom 13.36 ± 4.23 13.66 ± 3.56 12.45 ± 3.55
Placebo 13.51 ± 3.09 13.29 ± 3.29 12.95 ± 2.90
CRE (mg/dl) Oyster mushroom 0.69 ± 0.11 0.71 ± 0.12 0.69 ± 0.11
Placebo 0.69 ± 0.13 0.71 ± 0.12 0.69 ± 0.12
UA (mg/dl) Oyster mushroom 4.33 ± 1.17 4.31 ± 1.12 4.25 ± 1.31
Placebo 4.52 ± 1.32 4.54 ± 1.31 4.53 ± 1.46
TC (mg/dl) Oyster mushroom 211.77 ± 35.41 206.32 ± 30.32 211.91 ± 33.39
Placebo 216.64 ± 35.03 213.68 ± 34.27 212.54 ± 40.31
LDL-C (mg/dl) Oyster mushroom 122.91 ± 29.38 114.32 ± 27.91 120.27 ± 30.54
Placebo 131.00 ± 29.65 122.08 ± 28.82 122.96 ± 32.16
HDL-C (mg/dl) Oyster mushroom 86.59 ± 19.33 81.82 ± 16.82 85.23 ± 16.94
Placebo 80.40 ± 21.40 78.56 ± 21.10 79.08 ± 20.69
TG (mg/dl) Oyster mushroom 62.91 ± 22.06 68.64 ± 27.58 64.68 ± 17.51
Placebo 86.64 ± 70.18 85.68 ± 69.49 86.13 ± 72.10
FPG (mg/dl) Oyster mushroom 87.05 ± 8.89 86.00 ± 8.28 87.09 ± 9.55
Placebo 85.84 ± 5.20 86.44 ± 8.94 86.63 ± 5.26
HbA1c (%) Oyster mushroom 5.28 ± 0.37 5.25 ± 0.36 5.28 ± 0.38
Placebo 5.22 ± 0.31 5.19 ± 0.32 5.20 ± 0.33
Values are mean ± standard deviation (SD). WBC; white blood cells, RBC; red blood cells, Hb; hemoglobin, Ht; hematocrit, Plt; platelet count, AST; aspartate aminotransferase,
ALT; alanine aminotransferase, g-GTP; gamma glutamyl transpeptidase, ALP; alkaline phosphatase, LDH; lactate dehydrogenase, BUN; blood urea nitrogen, CRE; creatinine,
UA; ureic acid, TC; total cholesterol, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, TG; triglyceride, FPG; fasting plasma glucose,
HbA1c; hemoglobin A1c.
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to better understand the cytokine proﬁle, and found some increase
in the level of Th1-type cytokine TNF-a (P ¼ 0.115) and minimal
change in that of Th2-type IL-5 (P ¼ 0.265) at week 8 (Fig. 4). IL-4
plasma levels were too low to be measured in almost subjects
(data not shown). Increase of TNF-a is compatible with Th1-type
increase and would be functional for suppression of tumor
growth. In fact, TNF-a participates in the induction of IFN-g in an
additive fashion in the presence of cofactors such as IFN-a, resulting
in NK cell activation. Overall, it was strongly suggested that Oystermushroom extract stimulates the release of Th1-type cytokines,
and minimally affects that of Th2-type cytokines.3.4. Effects of Oyster mushroom on NK cell activity
To further conﬁrm the effect of Oyster mushroom extract on
activation of the immune system, particularly cell-mediated im-
munity, we evaluated NK cell activity. Because of up-regulation of
INF-g, the increase of NK cell activity was expected. Accordingly, we
Fig. 2. Changes in the plasma levels of IFN-g and IL-12. Values are means ± standard errors (SEs). Black bar, Oyster mushroom; Gray bar, placebo. Blood samples were collected at
weeks 0, 4 and 8. The plasma levels of IFN-g and IL-12 were measured as described in “Materials and Methods.” The statistical analysis was carried out by SPSS. *Statistically
signiﬁcant, P value less than 0.05.
Fig. 3. Changes in the plasma levels of IL-10 and IL-13. Values are means ± standard errors (SEs). Black bar, Oyster mushroom; Gray bar, placebo. Blood samples were collected at
weeks 0, 4 and 8. The plasma levels of IL-10 and IL-13 were measured as described in “Materials and Methods.” The statistical analysis was carried out by SPSS.
Fig. 4. Changes in the plasma levels of TNF-a and IL-5. Values are means ± standard errors (SEs). Black bar, Oyster mushroom; Gray bar, placebo. Blood samples were collected at
weeks 0, 4 and 8. The plasma levels of TNF-a and IL-5 were measured as described in “Materials and Methods.” The statistical analysis was carried out by SPSS.
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statistically signiﬁcant at week 8 (Fig. 5).
4. Discussion
The fruit body of P. Cornucopiae (Oyster mushroom, Tamogitake)
has traditionally been used as a health food for the prevention ofhypertension, diabetes and cancer.12 In the present study, we
examined the effect of Oyster mushroom extract in the human diet,
focusing on the activation of immune reactions by evaluating
cytokine proﬁles, particularly the Th1/Th2 balance. For example, IL-
4 inhibits IFN-g-dependent activation of macrophage effector
function. Conversely, IFN-g antagonizes the IL-4 dependent in-
duction of IgE receptors.13e15 In this study, we demonstrated that 8-
Fig. 5. Changes in the percentage of NK cell activity. Values are means ± standard
errors (SEs). Black bar, Oyster mushroom; Gray bar, placebo. Chromium-51 (51Cr)
release assays were used for the precise and accurate quantiﬁcation of cytotoxicity. The
method of measuring NK cell activity was described in “Materials and Methods.” The
statistical analysis was carried out by SPSS.
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duction in a randomized, double-blind, placebo-controlled,
parallel-group clinical study. A strong IFN-g producer, IL-12 was
also increased, but to a lesser extent. On the other hand, Th2-type
cytokines such as IL-10 and IL-13 were minimally changed, and
IL-4 was undetected because of low production.
It is unclear on the reason why Th2-type cytokines were mini-
mally changed by the intake of Oyster mushroom extract in spite of
increase of IFN-g. Oyster mushroom extract may have unknown
functional molecules to modulate the event of Th1/Th2 balance. As
another possible cause of lower level of Th2-type cytokines, the
assay system, multiplex beads kits used in the study, was relatively
less sensitive to Th2-type cytokines than Th1-type cytokines, e.g.,
IFN-g. Currently, we plan another clinical trial to answer these
questions, in which higher amount of Oyster mushroom extract is
used to produce sufﬁcient amount of Th1- and Th2-type cytokines
to obtain more deﬁnite results.
IFN-g is major product of Th1-type cells and drives the immune
response toward a Th1 phenotype. IFN-g achieves this by pro-
moting characteristic Th1 effector mechanisms, innate cell-
medicated immunity via activation of NK cells, and macrophage
activation.16 As for NK cell activity, the increase we measured was
relatively lower than expected from the increased level of IFN-g.
The reason for the minimal increase of NK cell activity in this study
remains to be elucidated. According to information from the SRL
engaged in the assay of NK cell activity, subjects with less than 20%
(normal range; 18e40% in SRL) of NK cell activity are appropriate to
be included for assessment of immune response. Thus, it is
considered that subjects recruited in this study had a relatively high
NK cell activities, 35.0% and 32.6% for Oyster mushroom extract and
placebo, respectively. Accordingly, the relatively higher NK cell
activities of the subjects might cause minimal change of NK cell
activity.
As for another possible reason for insigniﬁcant enhancement of
NK cell activity, the amount of Oyster mushroom extract may not
have been sufﬁcient. In terms of the biological actions of Oyster
mushrooms, it is well recognized to have the potential to reduce
blood pressure, but we found little change of blood pressure in the
current study. In this context, we might obtain unequivocal resultsfor the activation of NK cell activity if we use a higher amount of
Oyster mushroom extract for subjects with lower level of NK cell
activities, but this hypothesis needs further investigation by
another clinical trial integrating the current results.
Macrophages respond to a wide range of different cell products
(cytokines) during the innate and acquired immune response. Of
these, IFN-g is among the most important. Macrophages activated
with IFN-g induce direct anti-microbial and anti-tumor actions
through antigen processing and presentation pathways.17 In brief,
the mechanism as for antitumor action involves ampliﬁcation of
Type-1, increases of IFN-g and Th1 development, enhancement of
cytotoxic T-lymphocyte activity, or augmentation of NK cell acti-
vation and lytic ability. In this context, it is very likely that Oyster
mushroom extract stimulates macrophages by INF-g which results
in enhancement of immune system leading to protection of us from
infection and tumorigenesis.
The potential of Oyster mushroom extract to protect us from
acute and chronic diseases has already been demonstrated by an-
imal experiments using Sarcom180 mice cells.18 Speciﬁcally, it
showed that orally administered water extract of Oyster mushroom
inhibited the growth of Sarcoma180 in ICR mice, thereby demon-
strating an anti-tumor effect. Further, Oyster mushroom extract
induced costimulatory molecule expression and IL-12 secretion by
dendritic cells. The study also found that CD25/GITR-positive reg-
ulatory T cells were decreased in tumor-bearing mice administered
Oyster mushroom extract. These previous animal experimental
data well support the current results of the human clinical trial
demonstrating Oyster mushroom extract showing the potential to
increase Th1-type cytokines, namely IFN-g.
In terms of the mechanism of Oyster mushroom, the constitu-
ent(s) responsible for up-regulation of immune response by the
current Oyster mushroom extract has not been deﬁnitively iden-
tiﬁed. It has been reported that Oyster mushroom contains beta-D-
glucose, ergosterol, mannitol, phenolic compounds, linoleic acid,
peptides, and carbohydrates.19 As for b-glucan, many isolated
polysaccharides and protein-bound polysaccharides from A. blazei
have been shown to have direct anti-tumor activity.20 It was re-
ported that a tea preparation of A. blazei extracts was anti-
mutagenic in Chinese hamster lung ﬁbroblasts.21 Similarly to
A. blazei, the mushroom Letinus edodes also was observed to be
effective in protecting cells from DNA damage.
The constituent or constituents responsible for the anti-
mutagenic activity of edible Oyster mushrooms remain to be
identiﬁed. The Oystermushroom extract used in this study contains
24mg/pack of b-glucan, which is considered to be a direct activator
of the immune system. In comparison with previous reports from
other institutes, the Oyster mushrooms used in this study may
contain enough b-glucan to induce immune-protective action
against infectious diseases and tumorigenesis.
In recent years, various new foods have attracted attention as
health-beneﬁcial foods and as source materials for disease pre-
vention and health promotion supplements. In particular, herbal
and ﬁshery medicine derived from plant and ﬁsh extracts is being
increasingly utilized to prevent a wide variety of diseases despite
relatively little knowledge regarding their mechanism of action. In
this literature, we demonstrated that Oyster mushroom extract up-
regulates the immune system by release of IFN-g. In this sense,
Oyster mushrooms would be one of the promising candidates for
prevention of infectious and non-infectious diseases.
Lastly, it would be of interest to try to elucidate the mechanism
of action for Oyster mushroom extract in further studies. As for the
defense mechanism in terms of cytokine proﬁles and the immune
system, IFN-g production is controlled by cytokines secreted by
antigen-presenting cells (APCs), e.g., macrophages, most notably IL-
12 and IL-18.22 These cytokines serve as a bridge to link infection
A. Tanaka et al. / Journal of Traditional and Complementary Medicine 6 (2016) 424e430430with IFN-g production in the innate immune response. Macrophage
recognition of many pathogens induces secretion of IL-12 and
chemokines (e.g., macrophage-inﬂammatory protein-1a (MIP-
1a)).23 These chemokines attract NK cells to the site of inﬂamma-
tion, and IL-12 promotes IFN-g synthesis in these cells. We are
planning to design a human clinical trial focusing on these path-
ways to elucidate the mechanism of Oyster mushrooms in terms of
immune system responses to various diseases, including cancer.
5. Conclusion
In conclusion, we revealed that Oyster mushrooms potentiate
the immune system, through Th1 phenotype potentiation as the
macrophage-IL-12 e IFN-g pathway. Thus, Oyster mushroom
extract may be beneﬁcial for the prevention of various diseases by
stimulation of the immune system.
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